Sugi Predict

Sugi Predict / Compounds / SCHEMBL4425694

SCHEMBL4425694

SCHEMBL4425694

O=CCC(NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 3/20 0.54
▸ PPARG P37231 1/20 0.54
▸ CTSK P43235 3/20 0.53
▸ TACR1 P25103 2/20 0.53
▸ CTRB1 P17538 2/20 0.52
▸ CTSL P07711 1/20 0.52
▸ CTSB P07858 1/20 0.52
▸ CTSS P25774 1/20 0.52
▸ IDO1 P14902 1/20 0.52
▸ TDO2 P48775 1/20 0.52
▸ CASP1 P29466 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ ITGB3 P05106 2/20 0.51
▸ ITGA2B P08514 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8299708 1.00 PPARA (0.54) PPARAPPARGCTSKTACR1CTRB1
SCHEMBL3188496 0.91 CTSK (0.53) CTSKTACR1CTRB1CTSLCTSB
SCHEMBL16862505 0.91 CTSK (0.53) CTSKTACR1CTRB1CTSLCTSB
SCHEMBL15381002 0.89 ALDH1A1 (0.58) CTSKTACR1CTRB1CTSLCTSB
SCHEMBL419572 0.89 KYNU (0.60) CTSKTACR1CTRB1CTSLCTSB
SCHEMBL13244808 0.89 KYNU (0.60) CTSKTACR1CTRB1CTSLCTSB
SCHEMBL25636446 0.89 ALDH1A1 (0.58) CTSKTACR1CTRB1CTSLCTSB
SCHEMBL27543998 0.88 CTSK (0.67) CTSKCTSLCTSBCTSS
SCHEMBL924114 0.87 PPARA (0.53) PPARAPPARGCTSKTACR1CTRB1
SCHEMBL1162401 0.87 PPARA (0.53) PPARAPPARGCTSKTACR1CTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049064-A2 CARDIOPROTECTIVE LIPIDS AND METHODS OF USE SIGNPATH PHARMA INC. (US) 2025-03-06 — — WO disclosed
US-20240122930-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS, INC. 2024-04-18 — — US disclosed
EP-3538526-B1 CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-10 — — EP disclosed
EP-4329755-A1 EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS Pliant Therapeutics, Inc. (US) 2024-03-06 — — EP disclosed
EP-4328230-A2 AMINO ACID COMPOUNDS AND METHODS OF USE Pliant Therapeutics, Inc. (US) 2024-02-28 — — EP disclosed
CN-117615760-A Extended dosage regimen for integrin inhibitors 普利安特治疗公司 2024-02-27 — — CN disclosed
WO-2024015717-A2 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS, INC. (US) 2024-01-18 — — WO disclosed
EP-3761980-B1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS INC (US) 2023-11-29 — — EP disclosed
WO-2023225119-A1 STABILIZATION OF INTEGRIN INHIBITORS PLIANT THERAPEUTICS, INC. (US) 2023-11-23 — — WO disclosed
CN-110312533-B Prodrugs of cytotoxic active agents having enzymatically cleavable groups 拜耳公司 2023-11-03 — — CN disclosed
EP-0565396-B1 1-[2-(arylsulfonylamino)-1-oxoethyl]piperidine derivatives, their preparation and use in therapy SYNTHELABO (FR) 1998-01-07 — — EP disclosed
US-5585498-A Imidazole derivatives useful as synthetic intermediates SYNTHELABO (FR) 1996-12-17 — — US disclosed
US-5552410-A 1,2,3,4,-tetrahydroquinoline-8-sulphonic acid chlorides and acids, their preparation and their use as synthetic intermediates SYNTHELABO (FR) 1996-09-03 — — US disclosed
US-5476942-A 1-[2-amino-5-[1-(triphenylmethyl)-1H-imidazol-4-YL]-1-oxopentyl] piperidine derivatives, their preparation and their use as synthetic intermediates SYNTHELABO (FR) 1995-12-19 — — US disclosed
US-5453430-A Anticoagulants SYNTHELABO (FR) 1995-09-26 — — US disclosed
EP-0643047-A1 1(2-amino-5-(1-(triphenylmethyl)-1H-imidazol-4-yl)-1-oxopentyl)piperidine derivatives, their preparation and their use as synthetic intermediates SYNTHELABO (FR) 1995-03-15 — — EP disclosed
EP-0643046-A1 1,2,3,4-Tetrahydrochinolin-8-sulfonic acid and its chlorides as intermediates SYNTHELABO (FR) 1995-03-15 — — EP disclosed
EP-0614986-A1 Enzymatic racemate cleavage of 2-pipéridine alkylcarboxylates and their use as synthesis intermediates SYNTHELABO (FR) 1994-09-14 — — EP disclosed
EP-0579277-A1 Imidazole derivatives, their preparation and their use as synthetic intermediates SYNTHELABO (FR) 1994-01-19 — — EP disclosed
EP-0565396-A1 1-(2-arylsulfonylamino)-1-oxoethyl)-piperidine derivatives, their preparation and use in therapy SYNTHELABO (FR) 1993-10-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240122930-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS ITGB6, ITGA6, ITGAV PPARA 204/4885PPARG 305/4885CTSK 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.